The researchers found that socioeconomic status likely drives survival disparities between Hispanic patients and non-Hispanic whites (NHWs). They also found that, while both underserved populations, Hispanics and non-Hispanic blacks have different survival outcomes compared with NHWs.
Having a lower socioeconomic status (SES) drives disparities in survival outcomes for Hispanic patients with multiple myeloma, indicate new study findings.
Previous research has indicated that racial/ethnic minorities, including Hispanics and non-Hispanic blacks (NHBs), are disproportionately affected by low SES and are less likely to receive novel treatments. Research has also suggested that addressing this disparity could help improve outcomes. Data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database have showed that when treated similarly, NHB patients have significantly improved survival compared with non-Hispanic white (NHW) patients.
With similar insights lacking for Hispanics, researchers leveraged data from the same database, finding that SES likely drives survival disparities between Hispanic patients and NHWs. They also found that, while both underserved populations, Hispanics and NHBs have different survival outcomes compared with NHWs.
“Even though Hispanics and NHBs demonstrate similar and greater social and health challenges than NHWs at diagnosis, the survival disparities between these two underserved populations and NHWs are markedly different,” wrote the group. “When treated similarly, Hispanics and NHWs have comparable overall survival while NHBs have significantly longer survival than NHWs. In addition, among patients with low SES, NHBs have better survival than demographics-matched Hispanics. These findings indicate NHBs may harbor a more indolent disease subtype than other racial/ethnic groups.”
When determining differences in survival patterns between Hispanic patients and NHW patients, the researchers relied on SEER data from nearly 1600 Hispanics and over 20,000 NHWs, finding that Hispanics were more than twice as likely to have low SES (52.6% vs 23.1%).
Compared with demographics-matched NHWs, Hispanics had significantly worse median survival (30 vs 37 months) and 5-year survival rates (absolute difference, 3.6%). However, when they adjusted for SES, the differences were no longer significant (30 vs 32 months and absolute difference 2.2%, respectively). The group also found that when adjusting for demographic variables, being of Hispanic ethnicity was associated with increased risk of mortality but the association no longer remained when adjusting for SES, presentation, or treatment factors.
Stratification analyses showed that even if both Hispanics and NHWs were at a low SES, Hispanic patients still had an 18% increased risk of all-cause mortality compared with demographic-controlled NHWs.
“These results highlight the need to better understand factors beyond SES that impact MM survival disparities,” commented the researchers. “However, limited by the large number of missing values in disease-specific mortality, we were not able to assess MM-specific mortality to further examine whether comorbidities and treatments also impact MM-specific mortality. Of note, both comorbidities and treatment are important modifiable factors that may be affected by SES, providing us opportunities to eliminate these disparities.”
Reference
Buradagunta C, Garacci Z, D’Souza A, et al. Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. Blood Cancer J. Published online May 25, 2022. doi:10.1038/s41408-022-00681-x
CAR T Proves Effective and Safe for Refractory Multiple Myeloma
May 15th 2024Due to increasing reports of multiple myeloma and the emergence of chimeric antigen receptor (CAR) T-cell therapy as a treatment option, these investigators conducted a comprehensive review of the medical literature on the latest CAR T developments in the MM space.
Read More
Study Urges Personalized Care to Boost Quality of Life in Patients With MM
April 11th 2024Treatment and management of multiple myeloma (MM) is continuously evolving, and in this analysis, investigators discuss ever-present issues and potential solutions to optimize care for this patient population.
Read More
FDA Approves Cilta-Cel for Earlier Treatment of RRMM
April 6th 2024Most recently, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend ciltacabtagene autoleucel (Carvykti; Johnson & Johnson) in patients who have received at least 1 line of treatment for relapsed/refractory multiple myeloma (RRMM).
Read More
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More